Uveal Melanoma (UM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Ocular melanoma, a type of cancer that originates in the pigment-producing cells of the eye or surrounding area, is a relatively uncommon condition. The two subtypes of ocular melanoma are the uveal and conjunctival forms, which display notable differences. The presentation of ocular melanoma can vary depending on its location and may manifest as symptoms such as blurred vision, reduced visual field, flashing lights, redness, discomfort, pain, or a sensation of pressure. Several risk factors for the development of ocular melanoma have been identified, including fair skin, atypical skin moles, light eye color, iris moles, freckles, and exposure to sun or tanning, as well as a genetic correlation at the CLPTM1L locus between uveal and cutaneous melanoma. The primary mechanisms underlying the development of ocular melanoma may involve oxidative damage to pigmented tissues and genetic alterations resulting from adenine-to-cytosine mutations in uveal melanoma or adenine-to-thymine mutations in ciliochoroidal melanoma. Melanomas may also arise from pre-existing benign lesions known as nevi. The size of the melanoma guides the choice of treatment, which may include plaque radiation therapy, particle beam radiotherapy, transpupillary thermotherapy, laser photocoagulation, gamma knife stereotactic radiosurgery, local surgical resection, or enucleation. A definitive diagnosis of ocular melanoma requires a biopsy, as several other conditions may present similarly, including choroidal nevus, iris nevus, retinal pigment epithelium hypertrophy, and various benign or malignant lesions. Approximately half of the patients with ocular melanoma will develop metastatic disease within 10 to 15 years of diagnosis, with a smaller proportion developing metastases later, 20 to 25 years after initial diagnosis. Metastatic disease is universally fatal.

·       The incidence of uveal and conjunctival melanoma is estimated to be 5 cases per million and 0.33 cases per million in the USA. Males have a 30% greater incidence of uveal melanoma than females.

 

Thelansis’s “Uveal Melanoma (UM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uveal Melanoma (UM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Uveal Melanoma (UM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Uveal Melanoma (UM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Uveal Melanoma (UM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Uveal Melanoma (UM), Uveal Melanoma (UM) market outlook, Uveal Melanoma (UM) competitive landscape, Uveal Melanoma (UM) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more